Not finding it? Sign in to also search OpenAlex live.
-
The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.
Hans A. J. Gelderblom, Victoria E. H. Wang, Mark Doherty, Ana Sebio, Silvia Stacchiotti, Breelyn Ann Wilky, +14 more
5citations -
OP35 Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn’s Disease - Week 48 analysis of the STARDUST trial2021 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease
Silvio Danese, Severine A.R.A. Vermeire, Geert D’Haens, Julián Panés, Axel U Dignass, Fernando Magro, +7 more
2citations -
P0872 Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn’s disease: Phase 3 GRAVITI study results through week 482025 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
A Hart, Remo Panaccione, Flavio Steinwurz, Qian Cao, Tadakazu Hisamatsu, Stéphane Nancey, +5 more
0citations -
P319 Characteristics of filgotinib-treated patients with Ulcerative Colitis who achieve sustained corticosteroid-free remission: Post hoc analysis of the phase 2b/3 SELECTION study2023 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Teruaki Kobayashi, AU Dignass, Xavier Roblin, Y Fujitani, Alessandra Faria Oortwijn, C Jamoul, +1 more
0citations -
PB1432 Small Interfering RNA-mediated Inhibition of Endothelial Von Willebrand Factor in Pro-Atherothrombotic Mice2023 Research and Practice in Thrombosis and Haemostasis conference-abstract Medicine Platelet Disorders and Treatments Open access
Yvonne K. Jongejan, Annika de Jong, Richard J. Dirven, Amanda C. M. Pronk, Sander Kooijman, Jeroen C.J. Eikenboom, +1 more
0citations -
P678 Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE2024 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
B G Feagan Senior Scientific Officer, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Severine A.R.A. Vermeire, Silvio Danese, +8 more
0citations -
Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis2023 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, Jun‐ichi Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
0citations -
Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7.2024 Journal of Clinical Oncology conference-abstract Medicine Lymphoma Diagnosis and Treatment Open access
Leslie A. Lori, Lorenzo Falchi, Joost S.P. Vermaat, Gerardo Musuraca, David Belada, Marcel Nijland, +8 more
9citations -
Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial
Lorenzo Falchi, Anna Sureda, Sirpa Leppä, Joost S.P. Vermaat, Marcel Nijland, Jacob Haaber Christensen, +14 more
12citations -
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.2023 Journal of Clinical Oncology conference-abstract Medicine Lymphoma Diagnosis and Treatment Open access
Reid W. Merryman, David Belada, Anna Sureda, Sirpa Leppä, Joost S.P. Vermaat, Harald Holte, +13 more
10citations -
Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
Lori Ann Leslie, Chan Yoon Cheah, Franck Morschhauser, Justin M. Darrah, Joshua Brody, David Belada, +8 more
9citations -
Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7
Lori Ann Leslie, Gerardo Musuraca, Pau Abrisqueta, Joshua Brody, Jacob Haaber Christensen, Alexander Fosså, +8 more
2citations -
P083 How are beliefs about osteoporosis medicines elicited and addressed in clinical consultations: a video observational study2023 Lara D. Veeken conference-abstract Health Professions Patient-Provider Communication in Healthcare Open access
Ashley Hawarden, Laurna Bullock, Montserrat León‐García, Sandra A. Hartasanchez, Ian G Hargraves, Rob Horne, +4 more
1citations -
A century of sedimentation in a reservoir in central Europe – sedimentation rate and characteristics2022 conference-abstract Earth and Planetary Sciences Geological formations and processes Open access
Georg Stauch, Alexander Esch, Lukas Dörwald, Verena Esser, Simone Lechthaler, Frank Lehmkuhl, +2 more
0citations
20 results